Island Pharmaceuticals Ltd (ila) Logo

Island Pharmaceuticals Ltd (ILA)

___:___ · Healthcare
ASX Delayed
Cboe Live

What is live streaming pricing?

Stock prices will auto-update without reloading the page. How it works:

  • Flashing prices signify an increase (green) or decrease (red) from previous price. Otherwise, price is unchanged.
  • Expect a short delay while pricing data initially loads.
  • Note, prices only update during market hours (10am-4:13pm AEST).

More about Cboe Live pricing.

OK, got it
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE
Overview
Financials

ILA ASX Chart

Snapshot

Island Pharmaceuticals Limited (ILA) is a clinical-stage drug repurposing company, developing antiviral therapeutics to address infectious diseases. ISLA-101, a drug with an established safety profile is being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

Share Price Activity (ASX)

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2024 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -29.82%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,998 of 2,382
Sector Rank 195 of 226

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies IXC / MEB / HMD
EPS -$0.027
DPS $0.00
Book Value Per Share $0.016

Broker Consensus

ILA is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Top Market Index News

More News

Announcements

Price Sensitive only

Corporate Overview

Corporate Details

Head Office Camberwell VIC 3124
Website www.islandpharmaceuticals.com
Registry Automic Group
Auditor William Buck Audit (VIC) Pty Ltd
Date Listed 13 Apr 2021

Upcoming Calendar (Forecasted)

Date Event
28/08/2024 Report (Prelim)
28/08/2024 Report (Annual)
11/10/2024 Report (Annual)
28/10/2024 Report (Quarterly)

Former Company Names

  • Island Pharmaceuticals Ltd has no former company names.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors

Management

Director Transactions

ILA directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
26/03/24 Paul MacLeman Issued 33,572 $0.060 $2,014 Rights issue
26/03/24 Paul MacLeman Issued 33,572 $0.060 $2,014 Rights issue
26/03/24 David Foster Issued 20,588 $0.060 $1,235 Rights issue
26/03/24 David Foster Issued 500,000 $0.060 $30,000 Rights issue
26/03/24 David Foster Issued 520,588 $0.060 $31,235 Rights issue
26/03/24 David Brookes Issued 40,000 $0.060 $2,400 Rights issue
26/03/24 David Brookes Issued 40,000 $0.060 $2,400 Rights issue
26/03/24 Anna Lavelle Issued 40,000 $0.060 $2,400 Rights issue
26/03/24 Anna Lavelle Issued 40,000 $0.060 $2,400 Rights issue
26/03/24 Albert Hansen Issued 166,667 $0.060 $10,000 Rights issue
26/03/24 Albert Hansen Issued 166,667 $0.060 $10,000 Rights issue
04/04/23 Albert Hansen Expiry 23,030 $0.070 $1,612 Options expired
03/08/22 David Foster Transfer 40,000 $0.185 $7,400 Off-market transfer
03/08/22 David Foster Transfer 40,000 $0.185 $7,400 Off-market transfer
03/08/22 David Foster Buy +31,303 $0.202 $6,327 On-market trade
21/06/22 David Foster Buy +40,000 $0.130 $5,200 On-market trade
18/11/21 David Brookes Issued 100,000 $0.250 $25,000 Director remuneration
18/11/21 Albert Hansen Issued 100,000 $0.250 $25,000 Director remuneration
18/11/21 Anna Lavelle Issued 100,000 $0.250 $25,000 Director remuneration

Director Interests

The current holdings of ILA directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Anna Lavelle 26/03/2024 N/A 140,000 440,000 N/A
Albert Hansen 26/03/2024 N/A 11,104,034 566,667 N/A
David Foster 26/03/2024 5,646,829 156,455 1,053,922 N/A
David Brookes 26/03/2024 N/A 140,000 440,000 N/A
Paul MacLeman 26/03/2024 1 118,625 2,358,572 N/A

Shareholder Info

Top 20 Shareholders
About the Data

Data supplied by Morningstar and accurate on Aug 9, 2023.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dr William James Garner 22,056,105 27.14%
Mr Jason Alan Carroll 12,626,500 15.54%
Kesa Partners Inc 10,837,367 13.34%
Dr David C Foster 5,146,829 6.33%
Manchester Explorer LP 2,771,376 3.41%
Citicorp Nominees Pty Limited 1,928,951 2.37%
Mr Andre Fraga Figueiredo 1,832,947 2.26%
Pr Perry Nominees Pty Ltd Donesk Family A/C 1,810,000 2.23%
Mr Alistair Robert Baker 1,105,885 1.36%
Mr Andrew David Walker & Mrs Angela Rosemary Walker 880,892 1.08%
Mr Richard M Hemry 679,340 0.84%
Mrs Patricia Fernandes Dias De Almeida 660,861 0.81%
Mrs Azam Mohsenin Moshiri 500,000 0.62%
J P Morgan Nominees Australia Pty Limited 475,000 0.58%
Bnp Paribas Nominees Pty Ltd And Ib Au Noms Retailclient Drp 440,143 0.54%
Mr Feng Li 400,000 0.49%
Mr Phillip Richard Perry & Mrs Tetyana Perry Doneska Super Fund A/C 390,000 0.48%
Mr Alan Giles Sauran & Mrs Suzanne Aubrun Nth Turramurra Cons S/F A/C 371,042 0.46%
Ms Jennifer Anne Ciro 340,000 0.42%
Candour Asset Management Pty Ltd No 1 A/C 327,000 0.40%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 46 224 129 241 54 694

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.

Name Last Notice Total Shares Shares Held (%)
William James Garner 09/08/2023 22,056,105 27.14
Jason Alan Carroll 27/03/2024 20,000,000 17.58
Albert Hansen 26/03/2024 11,104,034 9.76
David Charles Foster 26/03/2024 5,803,284 5.10

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
27-03-24 Jason Alan Carroll 7,400,000 15.50 17.58
26-03-24 David Charles Foster 591,891 6.44 5.10
26-03-24 Albert Hansen 266,667 13.38 9.76
27-04-23 Jason Alan Carroll 845,000 14.46 15.50

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2023 $0.095 30 June
2022 $0.145 30 June
2021 $0.280 30 June
ILA Historical Price Data (CSV)
Up to 20 years of EOD share price history

Important note:

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)

Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.